Genotropin
Short Bowel Syndrome
Northwestern Universityprotein_peptidePhase 4 / ApprovedDormant
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 51/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Short Bowel Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Glepaglutide Zealand Pharma | Phase 3 | B |
Loperamide Odense University Hospital | Phase 3 | B |
Apraglutide VectivBio AG | Phase 2 | B |
Crofelemer Napo Therapeutics, S.p.A. | Phase 2 | CCC |
Mono-[2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-6-chromanyl] succinate polyethylene glycol monoester Boston Children's Hospital | Phase 2 | CCC |
Glucagon-Like Peptide 2 Alberta Children's Hospital | Phase 1/2 | CCC |
GLUCAGON-LIKE PEPTIDE II | N/A | D |
fe203799 GlyPharma Therapeutics | Phase 1/2 | NR |
Same molecule, other indications
Genotropin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →